**Lycium barbarum polysaccharides protect mice from hyperuricaemia through promoting kidney excretion of uric acid and inhibiting liver xanthine oxidase**

Xin Yu a,*, Lu Zhang b,*, Ping Zhang c, Jia Zhi d, Ruinan Xing e and Lianqi He f

aDepartment of Nuclear Medicine, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China; bDepartment of Endocrinology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China; cDepartment of Endocrinology, Central Hospital of Fushun, Fushun, Liaoning, China; dDermatological Department, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, Fushun, Liaoning, China; eDepartment of Cardiology, Zhongshan Hospital Xiamen University, Xiamen, Fujian, China; fDepartment of Cardiology, Central Hospital of Fushun, Fushun, Liaoning, China

**ABSTRACT**

**Context:** Lycium barbarum L. (Solanaceae) polysaccharides (LBPs) are important active constituents that have demonstrated kidney protection.

**Objective:** This study investigated the effect of LBPs on hyperuricaemia and explored the underlying mechanism in mice.

**Materials and methods:** Thirty-six C57BL/6 mice were randomly divided into the control group, hyperuricaemia group, allopurinol group (5 mg/kg) and three LBP groups (n = 6). The LBP groups were treated orally with LBPs at 50, 100 and 200 mg/kg body weight for 7 days. We examined the levels of serum uric acid (SUA) and urinary uric acid (UUA), as well as xanthine oxidase (XOD) activities. mRNA and protein were quantified by quantitative real-time PCR and Western blotting, respectively.

**Results:** LBPs treatment (100 and 200 mg/kg) significantly reduced the SUA levels to 4.83 and 4.48 mg/dL, and markedly elevated the UUA levels to 4.68 and 5.18 mg/dL (p < 0.05), respectively, while significantly increased the mRNA and protein expression levels of renal organic anti-transporter 1 (OAT1) and organic anti-transporter 3 (OAT3), and markedly decreased the levels of glucose transporter 9 (GLUT9) (p < 0.05). Additionally, the serum XOD activities were reduced to 31.5 and 31.1 mU/mL, and the liver XOD activities were reduced to 80.6 and 75.6 mU/mL after treatment with 100 and 200 mg/kg LBPs (p < 0.01), respectively.

**Discussion and conclusions:** This study demonstrated the potential role of LBPs in reducing the uric acid level in hyperuricemic mice. A border study population should be evaluated. These results are valuable for the development of new anti-hyperuricaemia agents from LBPs.

**Introduction**

Hyperuricaemia, characterized by high blood uric acid levels, is a metabolic disease. Under the condition of chronic hyperuricaemia, uric acid is crystallized and deposited as monosodium urate in the joint, being closely correlated with gout. Xanthine oxidase (XOD), the key enzyme in purine metabolism in the liver, is responsible for catalysing purine to uric acid (Choi et al. 2005; George and Struthers 2009). Thus, reducing the activity of XOD could be used to treat hyperuricaemia. In addition to the synthesis of uric acid, molecules responsible for the secretion and reabsorption of uric acid in the kidney also contribute to abnormal uric acid levels in the blood, such as renal organic anti-transporter 1 (OAT1), organic anti-transporter 3 (OAT3) and glucose transporter 9 (GLUT9). Presently, two types of agents have been used in the treatment of hyperuricaemia: one mainly accelerates uric-acid metabolism, and the other is used primarily to inhibit the activity of XOD, such as allopurinol. However, these agents have many adverse reactions, such as allergic reactions, kidney dysfunction, gastrointestinal symptoms and fever (Chung et al. 2015; Yang et al. 2015). Therefore, a safer and more effective agent with no side effects is needed for the treatment of hyperuricaemia.

Lycium barbarum L. (Solanaceae), a traditional Chinese medicine, has the effects of nourishing the liver and kidney and replenishing vital essence to improve eyesight. Lycium barbarum polysaccharides (LBPs) are the main effective ingredient of Lycium barbarum, comprised of glucose, arabinose, galactose, mannose, xylose, rhamnose and fucose (Zeng et al. 2019; Liu et al. 2020). Studies have demonstrated that LBPs have multiple pharmacological functions, including antioxidant, anti-inflammatory, antitumor, immune regulation, neuroprotective, hypoglycaemic and hypolipidemic effects (Li XM et al. 2007; Miao et al. 2010; Cheng et al. 2015; Xing et al. 2016; Po et al. 2017; Tang ZY et al. 2017; Pop et al. 2020). Moreover, Li J et al. (2017) demonstrated the protective effects of LBPs in renal damage. Thus far, the use of LBPs to treat hyperuricaemia has not been reported. In this study, we examined the efficacy of LBPs in reducing the serum uric acid levels in a mouse model of
hyperuricaemia induced by potassium oxonate. We also investigated the possible mechanisms of this effect.

**Materials and methods**

**Chemicals and reagents**

LBPs (≥90%) were purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). Potassium oxonate (97%) and allopurinol (≥99%) was purchased from Sigma-Aldrich Co. LLC (Shanghai, China). Uric acid (UA), serum creatinine (SCr), blood urine nitrogen (BUN) and xanthine oxidase activity assay kit were purchased from Abcam Inc. (Cambridge, UK). The RNA isolation kit was obtained from Promega Biotechnology Co., Ltd. (Beijing, China). PrimeScript™ RT reagent kit with gDNA Eraser and TB Green® Premix Ex Taq™ II (Tli RNaseH Plus) was purchased from Takara Biomedical Technology Co., Ltd. (Dalian, China). Protease and phosphatase inhibitors were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Anti-OAT1, anti-OAT3 and β-actin antibody were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-GLUT9 was purchased from Abcam Inc. (Cambridge, UK). The Amersham ECL System was purchased from GE Healthcare (Pittsburgh, PA, USA). Other biochemical reagents and chemicals were of analytical grade.

**Animals**

Eight-week-old C57BL/6 male mice (Vital River Laboratory Animal Technology Co., Ltd., Beijing, China), weighing 20–25 g, were housed at room temperature (23 ± 1°C) under standard conditions: humidity of 50 ± 5%, allowing free access to water and food under 12 h light/dark cycle (light at 8:00 am). The study was approved by the Ethics Committee of Central Hospital of Fushun for Animal Experiments and was performed according to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication 85-23, 1985 revision).

Thirty-six mice were randomly divided into the control group, hyperuricaemia group, allopurinol (5 mg/kg) group and LBPs groups (50, 100 and 200 mg/kg) (n = 6). The concentrations of LBPs were determined according to the literature (Wu et al. 2010). Potassium oxonate, a urate oxidase inhibitor, was used to induce a hyperuricaemia mouse model (Stavric et al. 1975). In addition to the control group, the remaining five groups were intraperitoneally injected with potassium oxonate (250 mg/kg) at 8:00 am for seven consecutive days. Allopurinol or LBPs (50, 100 and 200 mg/kg) were orally administered at 9:00 am for seven consecutive days in the corresponding group.

Finally, whole blood was collected 1 h after the last administration on the 7th day. After coagulation for 1 h at room temperature, the blood was centrifuged at 4000 g for 10 min and the serum was collected. The urine was collected using a mouse metabolic cage. The serum and urine samples were stored at −20°C until analysis. The liver and kidney tissues of the mice were quickly separated on ice and stored at −80°C for testing.

**Blood and urine sample analyses**

The collected serum and urine samples of the mice were used to detect the levels of serum uric acid (SUA), SCr, BUN and urinary uric acid (UUA) according to the manufacturer’s instructions using appropriate kits.

**Serum and hepatic XOD activity analysis**

Briefly, the liver tissue of the mice was thoroughly homogenized in an ice bath by placing it in sodium phosphate buffer at pH 7.4. The homogenate was centrifuged at 4000 g for 20 min at 4°C to extract the supernatant for subsequent use. The serum and hepatic XOD activities were measured using the xanthine oxidase activity assay kit according to the manufacturer’s instructions. The absorbance of each well was measured at 570 nm using an Infinite M PLEX Fully Loaded Multimode Plate Reader (Tecan, Männedorf, Switzerland). Each assay was performed in duplicate. XOD activity (mU/mL) was calculated using the formula provided by the manufacturer’s instructions.

**RNA isolation and quantitative real-time PCR**

Total RNA was extracted from mouse renal tissue using the RNA isolation kit, and quantitative real-time PCR using PrimeScript™ RT reagent kit with gDNA Eraser and TB Green® Premix Ex Taq™ II (Tli RNaseH Plus) was performed according to our previous report (He et al. 2019) with the following primers: Slc22a6 (OAT1)-F: 5’-TCTGCTCCTCCTATGCTGGT-3’; Slc22a6 (OAT1)-R: 5’-GATGTAGCTGCCCTCGGTA-3’; Slc22a8 (OAT3)-F: 5’-GCCAACCAACGTGCTACA-3’; Slc22a8 (OAT3)-R: 5’-GATCCAGCCATCCAGCATG-3’; Slc2a9 (GLUT9)-F: 5’-GGCTGCTTCTCTCCCTATC-3’; Slc2a9 (GLUT9)-R: 5’-CTGAGGCTTTGTCCTCTTG-3’; GAPDH-F: 5’-AGTGTT TCCCTGTCCTCGTAG-3’; GAPDH-R: 5’-GCCGTGAGTGGAG TCACTACT-3’.

The relative mRNA expression levels of Slc22a6, Slc22a8 and Slc2a9 were normalized to that of GAPDH.

**Western blotting**

Protein extracts were obtained following the collection of kidney tissue in RIPA lysis buffer supplemented with protease and phosphatase inhibitors. Western blotting was performed as previously described (He et al. 2019). The PVDF membrane was incubated with anti-OAT1, anti-OAT3 or anti-GLUT9 at a dilution of 1:200–1:1000 overnight at 4°C. An antibody against β-actin (1:1000) was used as a loading control. A horseradish peroxidase-labeled secondary antibody was added for 1 h at room temperature, and the enzymatic substrate was added. The Amersham ECL System was used to develop the blot, and the films were scanned for quantification by densitometry using ImageJ software (National Institutes of Health, Bethesda, MD, http://imagej.nih.gov/ij/, 1997e2012).

**Statistical analysis**

All the data in this study were analysed using SPSS 17.0 software for Windows (IBM Corp., Armonk, NY, USA). The data were expressed as the means ± standard deviation (SD). Statistical comparisons between the two groups were performed by Student’s t-test. A P value <0.05 was considered statistically significant.
Results

Effect of LBPs on the SUA, SCR, BUN and UUA levels in mice with hyperuricemia

After intraperitoneal injection of potassium oxonate, the SUA level was significantly increased in the hyperuricaemia group compared with that in the control group ($p < 0.001$, Figure 1(A)), suggesting that the mouse model of hyperuricaemia was successfully established. The SUA levels in the allopurinol group were reduced compared with those in the hyperuricaemia group ($p < 0.001$, $p < 0.01$ and $p < 0.001$ compared with the control group). In the LBP (50, 100 and 200 mg/kg) groups, the SUA level was also decreased ($p < 0.05$, $p < 0.01$ and $p < 0.001$; Figure 1(A)).

At the same time, we examined the levels of SCR and BUN. Consistently, decreases in both the SCR levels and BUN levels were found in the LBP groups ($p < 0.05$, $p < 0.01$ and $p < 0.001$; Figure 1(B,C)).

We also examined the UUA levels in all groups. As shown in Figure 1(D), the levels of UUA in the LBP-administered hyperuricemic mice were increased compared with hyperuricemic mice without LPB treatment ($p < 0.05$ or $p < 0.01$), suggesting that LBPs affect the renal excretion of uric acid. What’s more, the acute toxicity study showed no significant changes in body weight (Figure 1(E)), respiration, behaviour changes or death, indicating the safety of the maximal tolerable dose of LBPs. Therefore, LBPs reduced the SUA levels in hyperuricemic mice likely by increasing the excretion of uric acid from the blood into urine.

Effect of LBPs on the protein and mRNA expression levels of OAT1, OAT3 and GLUT9 in kidney tissue of hyperuricemic mice

Many studies have demonstrated that certain molecules are responsible for the excretion and absorption of UA in the kidney, such as OAT1, OAT3 and GLUT9, which are encoded by Slc22a6, Slc22a8 and Slc2a9, respectively. To further investigate the mechanism, we performed quantitative real-time PCR to examine the mRNA levels of OAT1, OAT3 and GLUT9 in mouse kidney tissue in different groups. Compared with the control group, the mRNA levels of OAT1 and OAT3 were downregulated, and that of GLUT9 was upregulated, in the hyperuricaemia group ($p < 0.001$, Figure 2(A–C)), indicating that
the transport of UA from the blood into urine was inhibited in hyperuricemic mice. However, LBPs increased the mRNA levels of OAT1 and OAT3 but decreased the mRNA level of GLUT9 in a dose-dependent manner compared with the hyperuricaemia group (p < 0.05 or p < 0.01, Figure 2(A–C)).

We also detected the protein expression levels of OAT1, OAT3 and GLUT9 by western blot analysis. As shown in Figure 3, although the protein level of OAT3 was elevated in hyperuricemic mice treated with allopurinol (p < 0.01), no significant difference was found between the two groups above in the protein expression of OAT1 and GLUT9. However, the protein levels of OAT1 and OAT3 were significantly increased, and that of GLUT9 was decreased, in the LBP groups compared with those in the hyperuricaemia group (p < 0.05, p < 0.01 or p < 0.001; Figure 3). In summary, LBPs affect OAT1, OAT3 and GLUT9 expression, likely by regulating the excretion and absorption of SUA in the hyperuricemic mouse kidney.

**Effect of LBPs on XOD activities in the serum and liver of mice with hyperuricaemia**

We further determined whether LBPs decrease the SUA level in hyperuricemic mice by reducing its synthesis. To test this hypothesis, we tested the serum and hepatic XOD activity in mice. As expected, the serum and hepatic XOD activities were significantly increased in the hyperuricaemia group compared with those in the control group (p < 0.001, Figure 4(A,B)); by contrast, the serum XOD and hepatic XOD activities were significantly inhibited in the allopurinol group compared with those in the hyperuricaemia group (p < 0.01, Figure 4(A,B)). In the LBP (100 and 200 mg/kg) groups, the serum XOD and hepatic XOD activities were also inhibited compared with those in the hyperuricaemia group (p < 0.01, Figure 4(A,B)), indicating the potential mechanism of the decreased SUA levels in hyperuricemic mice treated with LBPs occurs by suppressing XOD activity.

**Discussion**

Hyperuricaemia is a metabolic disease caused by disorders of uric acid metabolism, which is characterized by elevated blood uric acid levels. Hyperuricaemia can cause gouty arthritis, renal insufficiency, systemic inflammation, cardiovascular disease, and other metabolic abnormalities (Abeles 2015; Cabau et al. 2020). Hyperuricaemia is mainly caused by insufficient excretion of uric acid by the kidneys or excessive uric acid production by the liver. Uric acid excretion disorders are caused primarily by abnormal urate transporters in the proximal tubules, such as OAT1 (Slc22a6), OAT3 (Slc22a8) and GLUT9 (Slc2a9) (Yong et al. 2017; Fang et al. 2019). Among them, OAT1 and OAT3 are used to excrete urate from the kidney into the urine, which is then excreted from the body, while GLUT9 regulates the reabsorption of urate (Yong et al. 2017; Fang et al. 2019). The excessive production of uric acid is mainly due to the enhanced activity of the key enzyme XOD during uric acid production or the large intake of purines in the diet (Tang et al. 2018). Therefore, regulation of these transporters in the kidney and XOD activity in the liver are key targets for the treatment of hyperuricaemia. Studies have shown that LBPs have protective effects on liver and kidney tissue (Li et al. 2017; Rjeibi et al. 2018; Liao et al. 2019). However, the effect of LBPs on hyperuricaemia remains unclear. In the present study, we observed that LBPs decreased the SUA levels in hyperuricemic mice in a dose-dependent manner. Moreover, the BUN and SCR levels were decreased in hyperuricemic mice treated with LBPs, indicating the protective effect of LBPs on the kidney and corroborating the findings of previous reports (Li et al. 2017; Rjeibi et al. 2017). Conversely, the SUA level was increased in hyperuricemic mice treated with LBPs. These data demonstrated that LBPs reduced the SUA levels, and the underlying mechanism is via increased UA excretion.

To test the hypothesis above, we assessed the mRNA expression levels of Slc22a6, Slc22a8 and Slc2a9 in the kidneys of each mouse group. The results showed that LBPs upregulated the expression levels of Slc22a6 and Slc22a8 but downregulated those of Slc2a9 in the hyperuricemic mouse kidney. At the protein level, LBPs increased the expression levels of OAT1 and OAT3 and decreased the expression level of GLUT9 in the hyperuricemic mouse kidney. These results indicated that LBPs reduce the level of uric acid in the blood by increasing the excretion of uric acid and reducing the reabsorption of uric acid by the kidney. The clinical first-line anti-hyperuricaemia drug benz bromarone works by strengthening the excretion of uric acid in the kidney's
Figure 3. Effect of LBPs on the protein levels of OAT1, OAT3 and GLUT9 in the kidney tissue of potassium oxonate-induced hyperuricemic mice. (A) The protein levels were measured by western blotting, and (B–D) densitometry was calculated. The data are presented as means ± SD, n = 6 per group. ###p < 0.001 compared with the control group. */p < 0.05, **p < 0.01 and ***p < 0.001 compared with the hyperuricaemia group.

Figure 4. Effect of LBPs on the (A) serum and (B) liver XOD activities of potassium oxonate-induced hyperuricemic mice. The data are presented as means ± SD, n = 6 per group. ###p < 0.001 compared with the control group. **p < 0.01 compared with the hyperuricaemia group.
proximal tubule, thereby maintaining blood uric acid at a suitable level. However, many studies have demonstrated the hepatotoxicity of benzbromarone (Wang et al. 2016, 2017), which restricted its usage in some countries, such as the United States.

Allopurinol is another clinical treatment for gout, mainly by inhibiting XOD activity, thereby reducing liver uric acid production. However, studies have reported that allopurinol may cause serious side effects such as rash, liver toxicity or gastrointestinal toxicity (Umamaheswari et al. 2009). Therefore, it is necessary to develop new anti-hyperuricaemia drugs. In the present study, we found that LBPs could significantly reduce XOD activity in the blood and liver of hyperuricemic mice. According to reports in the literature, the pharmacological effects of LBPs are related to their ability to scavenge oxygen free radicals (Li et al. 2007), and active oxygen species, including hydrogen peroxide (H2O2) and superoxide anion (O2−), are produced during the metabolism of purine (Berry and Hare 2004). These findings may explain why LBPs inhibit XOD activity, but further verification is needed.

**Conclusions**

Our study demonstrated that LBPs exert an anti-hyperuricaemia effect by increasing the expression of renal OAT1 and OAT3, decreasing the expression of renal GLUT9, and inhibiting XOD activity. The results obtained under our experimental conditions are valuable for the development of new anti-hyperuricaemia agents. Therefore, the anti-hyperuricaemia effect of LBPs on other animals should be further investigated.

**Disclosure statement**

The authors declare that there are no conflicts of interest.

**Funding**

This article was supported by the Natural Science Foundation of Liaoning Province [2020-BS-284].

**References**

Abbeles AM. 2015. Hyperuricemia, gout, and cardiovascular disease: an update. Curr Rheumatol Rep. 17:1936–1949.

Berry CE, Hare JM. 2004. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (Lond). 555:589–606.

Cabau G, Crisan TO, Kliick V, Popp RA, Joosten LAB. 2020. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol Rev. 294:92–105.

Cheng J, Zhou ZW, Sheng HP, He LJ, Fan WX, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, et al. 2015. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther. 9:33–78.

Choi HK, Mount DB, Reginato AM. American Physiological Society. 2005. Pathogenesis of gout. Ann Intern Med. 143:499–516.

Chung WH, Chang WC, Stocker SL, Joo CG, Graham GG, Lee MH, Williams KM, Tian YC, Juan KC, Jan Wu YJ, et al. 2015. Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 74:2157–2164.

Fang C, Chen L, He M, Luo Y, Zhou M, Zhang N, Yuan J, Wang H, Xie Y. 2019. Molecular mechanistic insight into the anti-hyperuricemic effect of Eucommia ulmoides in mice and rats. Pharm Biol. 57:112–119.

George J, Struthers AD. 2009. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 5:265–272.

He L, Tian X, Yan C, Liu D, Wang S, Han Y. 2019. Nicotine promotes the differentiation of C2C12 myoblasts and improves skeletal muscle regeneration in obese mice. Biochem Biophys Res Commun. 511:739–745.

Li XM, Ma YL, Liu XJ. 2007. Effect of the Lycium barbarum polysaccharides on age-related oxidative stress in aged mice. J Ethnopharmacol. 111:504–511.

Li J, Shi M, Ma B, Zheng Y, Niu R, Li K. 2017. Protective effects of fraction 4a of polysaccharides isolated from Lycium barbarum by KBrO3-induced renal damage in rats. Food Funct. 8:2566–2572.

Liao J, Liu B, Zhong W, Wang GD, Xu YL, Chen X. 2019. Protective effect of Lycium barbarum polysaccharides against high-fat diet-induced renal injury and lipid deposition in rat kidneys. J Biol Regul Homeost Agents. 33:7–17.

Liu L, Sha XY, Wu YN, Chen MT, Zhong JX. 2020. Lycium barbarum polysaccharides protects retinal ganglion cells against oxidative stress injury. Neural Regen Res. 15:1526–1531.

Miao Y, Xiao B, Jiang Z, Guo Y, Mao F, Zhao J, Huang X, Guo J. 2010. Growth inhibition and cell-cycle arrest of human gastric cancer cells by Lycium barbarum polysaccharide. Med Oncol. 27:785–790.

Po KK, Leung JW, Chan JN, Fung TK, Sanchez-Vidana DI, Sin EL, So SF, Lau BW, Siu AM. 2017. Protective effect of Lycium barbarum polysaccharides on dextromethorphan-induced mood impairment and neurogenesis suppression. Brain Res Bull. 134:10–17.

Pop C, Berce C, Ghibu S, Scurtu I, Sorliu O, Login C, Kiss B, Stefan MG, Fizean I, Silaghi H, et al. 2020. Effects of Lycium barbarum L. polysaccharides on inflammation and oxidative stress markers in a pressure over-load-induced heart failure rat model. Molecules. 25:466–477.

Rjeibi I, Feriani A, Ben Saad A, Ncib S, Sdarya J, Saidi I, Souid S, Hiafiedh N, Allagui MS. 2017. Phytochemical characterization and bioactivity of Lycium europaeum: A focus on antioxidant, antiinocceptive, hepatoprotective and nephroprotective effects. Biomed Pharmacother. 95:1441–1450.

Rjeibi I, Feriani A, Saad AB, Ncib S, Sdarya J, Hiafiedh N, Allagui MS. 2018. Lycium europaeum Limn as a source of polysaccharides with in vitro anti-oxidant activities and in vivo anti-inflammatory and hepatoprotective potentials. J Ethnopharmacol. 225:116–127.

Stavrak B, Clayman S, Gadd RE, Hebert D. 1975. Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun. 7:117–124.

Tang ZY, Sun D, Qian CW, Chen Q, Duan SS, Sun SY. 2017. Lycium barbarum polysaccharide alleviates nonlymphopenia exposure induced testicular injury in juvenile zebrafish. Int J Biol Macromol. 104:618–623.

Tang D, Zhang J, Zhou R, Xie YN, Hou X, Xu K, Wu P. 2018. Phosphorescent inner filter effect-based sensing of xanthine oxidase and its inhibitors with Mn-doped ZnS quantum dots. Nanoscale. 10:8477–8482.

Umamaheswari M, Asokkumar K, Sivashanmugam AT, Remyaraju A, Subhadra Devi V, Ravi TK. 2009. In vitro xanthine oxidase inhibitory activity of the fractions of Erythrina stricta. Rxb J. Ethnopharmacol. 124:646–648.

Wang H, Peng Y, Wang Q, Guo X, Huang W, Peng Z, Zhong J. 2016. Cystine-based protein aduction by epoxide-derived metabolite(s) of benzbromarone. Chem Res Toxicol. 29:2145–2152.

Wang H, Peng Y, Zhang T, Lan Q, Zhao H, Wang W, Zhao Y, Wang X, Pang J, Wang S, et al. 2017. Metabolic epoxidation is a critical step for the development of benzbromarone-induced hepatotoxicity. Drug Metab Dispos. 45:1354–1363.

Wang K, Wang H, Peng Y, Zhong J. 2016. Identification of epoxide-derived metabolite(s) of benzbromarone. Drug Metab Dispos. 44:607–615.

Wu HT, He XJ, Hong YK, Ma T, Xu YP, Li HH. 2010. Chemical characterization of Lycium barbarum polysaccharides and its inhibition against liver oxidative injury of high-fat mice. Int J Biol Macromol. 46:540–543.

Xing X, Liu F, Xiao J, So KF. 2016. Neuroprotective mechanisms of Lycium barbarum. Neurourol Urodyn. 18:253–263.

Yang CY, Chen CH, Deng ST, Huang CS, Lin YJ, Chen YJ, Wu CY, Hung SL, Chung WH. 2015. Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan. JAMA Intern Med. 175:1550–1557.

Zeng P, Li J, Chen Y, Zhang L. 2019. The structures and biological functions of polysaccharides from traditional Chinese herbs. Prog Mol Biol Transl Sci. 163:423–444.

Yong T, Chen S, Xie Y, Chen D, Su J, Shuai O, Jiao C, Zuo D. 2017. Hypouricemic effects of Gonosperma aplannatum in hyperuricaemia mice through OAT1 and GLUT9. Front Pharmacol. 8:996–1007.